Hovione's Tejo Campus in Seixal has entered into the final stage of its first construction phase, with the site set to be operational by mid 2027.
The $200m facility, which is the CDMO's second in Portugal, will have two specialised production buildings — one for particle engineering and one for final dosage forms.
The site will significantly expand Hovione's pharmaceutical manufacturing capacity, while incorporating automation to drive efficiency.
Once the facility is completed, the project will create around 100 high-skill roles.
Hovione currently operates manufacturing sites in Ireland, Macau and the US, as well as a facility in Loures, Portugal — so this novel build will support the company's production capabilities in the key European market.
“This new phase of Hovione Tejo´s construction is a major step in the company’s international expansion," notes Jean-Luc Herbeaux, CEO of Hovione.
"This greenfield expansion will enable Hovione to efficiently manufacture complex new medicines for our customers under stringent regulations. It will also create numerous direct and indirect qualified jobs, strengthening the pharmaceutical ecosystem in the beautiful region of Seixal."
"The products manufactured here will be exported worldwide, contributing to improving the health of millions of people," he noted.
On top of the production facilities at the site, Hovione will build supporting infrastructure, including laboratories, offices and a shared cafeteria.
The Seixal site's operations will begin in 2026 at a reduced employee capacity, which will increase to 100 members of staff once production starts.
“We have assembled a multidisciplinary team, drawing expertise from our entire organisation, to design a Campus that sets new standards. It will provide an exceptional environment for our team members, suppliers and customers, conducive to the development of new solutions based on high yield collaborations,” Dr Herbeax concluded.